Murat Fani Bozkurt1, Irene Virgolini2, Sona Balogova3,4, Mohsen Beheshti5,6, Domenico Rubello7, Clemens Decristoforo2, Valentina Ambrosini8, Andreas Kjaer9, Roberto Delgado-Bolton10, Jolanta Kunikowska11, Wim J G Oyen12, Arturo Chiti13, Francesco Giammarile14, Anders Sundin, Stefano Fanti8. 1. Hacettepe University Faculty of Medicine Department of Nuclear Medicine, Ankara, Turkey. fanibozkurt@yahoo.com. 2. Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria. 3. Department of Nuclear Medicine, Comenius University and St. Elisabeth Oncology Institute, Bratislava, Slovakia. 4. Department of Nuclear Medicine, Tenon Hospital AP-HP & Université Pierre et Marie Curie, Paris, France. 5. PET-CT Center, Department of Nuclear Medicine & Endocrinology, St. Vincent's Hospital, Linz, Austria. 6. Department of Nuclear Medicine, Paracelsus Medical University, Salzburg, Austria. 7. Department of Nuclear Medicine, PET Center and Medical Physics and Radiology, Santa Maria della Misericordia Hospital, Rovigo, Italy. 8. Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Bologna, Italy. 9. Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark. 10. Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, San Pedro Hospital and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, Spain. rbiolton@gmail.com. 11. Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland. 12. Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK. 13. Nuclear Medicine Department, Humanitas University, Rozzano, MI, Italy. 14. Nuclear Medicine, University of Lyon, Lyon, France.
Abstract
PURPOSE & METHODS: Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using 68Ga-DOTA-conjugated peptides, as well as 18F-DOPA imaging for various neuroendocrine neoplasms. RESULTS & CONCLUSION: The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with 68Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.
PURPOSE & METHODS:Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using 68Ga-DOTA-conjugated peptides, as well as 18F-DOPA imaging for various neuroendocrine neoplasms. RESULTS & CONCLUSION: The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with 68Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.
Authors: Damian Wild; Jamshed B Bomanji; Pascal Benkert; Helmut Maecke; Peter J Ell; Jean Claude Reubi; Martyn E Caplin Journal: J Nucl Med Date: 2013-01-07 Impact factor: 10.057
Authors: Alessio Imperiale; Thibault Bahougne; Bernard Goichot; Philippe Bachellier; David Taïeb; Izzie Jacques Namer Journal: Clin Nucl Med Date: 2015-08 Impact factor: 7.794
Authors: E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi Journal: Eur J Nucl Med Date: 1993-08
Authors: Daniel Putzer; Michael Gabriel; Benjamin Henninger; Dorota Kendler; Christian Uprimny; Georg Dobrozemsky; Clemens Decristoforo; Reto Josef Bale; Werner Jaschke; Irene Johanna Virgolini Journal: J Nucl Med Date: 2009-07-17 Impact factor: 10.057
Authors: A Chiti; S Fanti; G Savelli; A Romeo; B Bellanova; M Rodari; B J van Graafeiland; N Monetti; E Bombardieri Journal: Eur J Nucl Med Date: 1998-10
Authors: I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2007-05-23 Impact factor: 9.236
Authors: Dariusz Pawlak; Christine Rangger; Petra Kolenc Peitl; Piotr Garnuszek; Michał Maurin; Laura Ihli; Marko Kroselj; Theodosia Maina; Helmut Maecke; Paola Erba; Leopold Kremser; Alicja Hubalewska-Dydejczyk; Renata Mikołajczak; Clemens Decristoforo Journal: Eur J Pharm Sci Date: 2016-01-27 Impact factor: 4.384
Authors: E A Aalbersberg; B J de Wit-van der Veen; M W J Versleijen; L J Saveur; G D Valk; M E T Tesselaar; M P M Stokkel Journal: Eur J Nucl Med Mol Imaging Date: 2018-08-10 Impact factor: 9.236
Authors: Luca Giovanella; Giorgio Treglia; Ioannis Iakovou; Jasna Mihailovic; Frederik A Verburg; Markus Luster Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-04 Impact factor: 9.236
Authors: Manuel Weber; Lukas Kessler; Benedikt Schaarschmidt; Wolfgang Peter Fendler; Harald Lahner; Gerald Antoch; Lale Umutlu; Ken Herrmann; Christoph Rischpler Journal: BMC Cancer Date: 2020-04-16 Impact factor: 4.430